Ç÷¾×¾Ï Áø´Ü ½ÃÀå ±Ô¸ð, Á¡À¯À², µ¿Ç⠺м® º¸°í¼­ : Á¦Ç°º°, °Ë»çº°, ÃÖÁ¾ ¿ëµµº°, Áö¿ªº°, ºÎ¹® ¿¹Ãø(2025-2030³â)
Blood Cancer Diagnostics Market Size, Share & Trends Analysis Report By Product, By Test, By End-use, By Region, And Segment Forecasts, 2025 - 2030
»óǰÄÚµå : 1654152
¸®¼­Ä¡»ç : Grand View Research, Inc.
¹ßÇàÀÏ : 2025³â 01¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 150 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,950 £Ü 8,609,000
Unprintable PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠺Ұ¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 6,950 £Ü 10,055,000
Printable PDF (5-User License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ 5¸í±îÁö ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 8,950 £Ü 12,949,000
Printable PDF (Enterprise License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

Ç÷¾×¾Ï Áø´Ü ½ÃÀåÀÇ ¼ºÀå°ú µ¿Çâ

Grand View Research, Inc.ÀÇ ÃֽŠº¸°í¼­¿¡ µû¸£¸é ¼¼°èÀÇ Ç÷¾×¾Ï Áø´Ü ½ÃÀå ±Ô¸ð´Â 2030³â±îÁö 160¾ï 4,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµÇ¸ç 2025³âºÎÅÍ 2030³â±îÁö 6.87%ÀÇ CAGRÀ» ±â·ÏÇÒ °ÍÀ¸·Î Àü¸ÁµË´Ï´Ù.

ÀÌ ½ÃÀåÀº ¹éÇ÷º´, ¸²ÇÁÁ¾, °ñ¼öÁ¾°ú °°Àº Ç÷¾× ¾Ç¼º Á¾¾çÀÇ ¹ßº´·ü Áõ°¡¿¡ ÀÇÇØ ÁÖµµµÇ°í ÀÖ½À´Ï´Ù. Ç÷¾×¾ÏÀ» Æ÷ÇÔÇÑ ¸¸¼º Áúȯ¿¡ ´õ Ãë¾àÇÑ ³ëÀÎ Àα¸ÀÇ Áõ°¡·Î ÀÎÇØ ½ÃÀåÀº ´õ¿í Å©°Ô ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¶ÇÇÑ NGS ¹× ±âŸ ºÐÀÚ Áø´Ü ±â¼úÀ» Æ÷ÇÔÇÑ ±â¼ú ¹ßÀüÀ¸·Î Áø´ÜÀÇ Á¤È®¼º°ú È¿À²¼ºÀÌ Çâ»óµÇ¾î ¿¹Ãø ±â°£ µ¿¾È ½ÃÀåÀ» ÁÖµµ ÇÒ °¡´É¼ºÀÌ ³ô½À´Ï´Ù.

Áö³­ 10³â µ¿¾È Ç÷¾×¾Ï Áø´Ü¿¡ ´ëÇÑ Á¢±Ù ¹æ½ÄÀÌ Å©°Ô ¹ßÀüÇßÀ¸¸ç, ÀÌ´Â ¸ðµÎ Áõ°¡ÇÏ´Â Áúº´ÀÇ ¹ß»ý·ü°ú »ç¸Á·üÀ» ÁÙÀ̱â À§ÇÑ °ÍÀÔ´Ï´Ù. ÀÌ·¯ÇÑ ¹ßÀüÀº ¾Ï Á¶±â ¹ß°ß·üÀ» ³ôÀÌ´Â µ¥ µµ¿òÀÌ µÇ´Â °ÍÀ¸·Î Àß ¾Ë·ÁÁ® ÀÖÁö¸¸, »ó´çÇÑ ¹ßÀüÀÌ ÀÖ¾ú½À´Ï´Ù. ¿¹¸¦ µé¾î, NGS´Â ¾Ï¼¼Æ÷ÀÇ Àüü °Ô³ð ºÐ¼®À» °¡´ÉÇÏ°Ô ÇÏ¿© Á¤È®ÇÑ Áø´Ü°ú ¸ÂÃãÇü Ä¡·á¸¦ ¾È³»ÇÏ´Â À¯ÀüÀû µ¹¿¬º¯ÀÌ¿¡ ´ëÇÑ ÀλçÀÌÆ®¸¦ Á¦°øÇÕ´Ï´Ù. 2022³â 10¿ù, ½Ã½º¸ß½º ±×·ìÀÎ OGT´Â È®Àå ÁßÀÎ NGS Á¦Ç°±ºÀ» º¸°­Çϱâ À§ÇØ ´Ù¾çÇÑ »õ·Î¿î Á¦Ç°À» Ãâ½ÃÇß½À´Ï´Ù. ƯÈ÷ ´Ù¾çÇÑ °ñ¼ö¼º Áúȯ°ú °ü·ÃµÈ À¯ÀüÀû µ¹¿¬º¯À̸¦ ½Äº°Çϵµ·Ï ¼³°èµÈ SureSeq °ñ¼ö¼º Ç÷¯½º ÆÐ³ÎÀº ÀÌ Áß¿äÇÑ ¿¬±¸ ¿µ¿ª¿¡¼­ ȸ»çÀÇ ¿ª·®À» °­È­Çß½À´Ï´Ù.

SPECT/CT, PET ¹× À¯¼¼Æ÷ ºÐ¼®°ú °°Àº ºÐÀÚ À̹Ì¡ ±â¼úÀº ºÐÀÚ À̹Ì¡ ¿¡ÀÌÀüÆ®¸¦ »ç¿ëÇÏ¿© ´Ù¾çÇÑ Áúº´ ´Ü°è¿¡¼­ ÁöÇ¥ ºÐÀÚ ¸¶Ä¿¸¦ °¨ÁöÇÏ¿© °¨Áö ¹× ¸ð´ÏÅ͸µÀ» Áö¿øÇÕ´Ï´Ù. ÀÌ·¯ÇÑ À̹Ì¡ ±â¼úÀÇ ¹ßÀüÀ¸·Î Á¤È®µµ¿Í Á¶±â ¹ß°ß ±â´ÉÀÌ Çâ»óµÇ¾î ½ÃÀåÀ» ÁÖµµÇϰí ÀÖ½À´Ï´Ù. ¼¼°èÀÇ ±â¾÷µéÀº ½ÃÀå Á¡À¯À²À» ³ôÀ̱â À§ÇØ ÀÚµ¿ À̹Ì¡ °Ë»ç¿Í ½Ã½ºÅÛÀ» µµÀÔÇϰí ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î, 2023³â 5¿ù, ½Ã½º¸ß½º ÄÚÆÛ·¹À̼ÇÀº ÀϺ»¿¡¼­ ÀÓ»ó À¯¼¼Æ÷ ºÐ¼® ½Ã½ºÅÛÀ» Ãâ½ÃÇÑ´Ù°í ¹ßÇ¥Çß½À´Ï´Ù. ÀÌ ½Ã½ºÅÛ¿¡´Â À¯¼¼Æ÷ ºÐ¼®±â XF-1600, ½Ã·á Áغñ ½Ã½ºÅÛ PS-10, Ç×ü ½Ã¾à ¹× ±âŸ °ü·Ã Á¦Ç°ÀÌ Æ÷ÇԵ˴ϴÙ. ÀÌ ½Ã½ºÅÛÀ» ÅëÇØ ½ÇÇè½ÇÀº ½Ã·á ÁغñºÎÅÍ ÃøÁ¤ °á°ú º¸°í±îÁö À¯¼¼Æ÷ ºÐ¼® °Ë»çÀÇ Àüü ÇÁ·Î¼¼½º¸¦ ÀÚµ¿È­ÇÒ ¼ö ÀÖ¾î È¿À²¼º°ú °Ë»ç Ç¥ÁØÈ­¿¡ ±â¿©ÇÒ ¼ö ÀÖ½À´Ï´Ù.

¼¼°èÀÇ °¢±¹ Á¤ºÎ´Â ¹éÇ÷º´ ¹× ¸²ÇÁÁ¾°ú °°Àº Ç÷¾× ¾Ç¼º Á¾¾ç ¹ßº´·ü Áõ°¡·Î ÀÎÇÑ ¸·´ëÇÑ ÀÇ·á ºÎ´ãÀ» ÀνÄÇϰí ÀÖ½À´Ï´Ù. ÀÌ¿¡ µû¶ó ¸¹Àº ±¹°¡¿¡¼­ Á¶±â ¹ß°ß°ú °ËÁø ³ë·ÂÀ» ¿ì¼±½ÃÇÏ´Â Æ÷°ýÀûÀÎ ±¹°¡ ¾Ï °ü¸® ÇÁ·Î±×·¥À» ½ÃÀÛÇß½À´Ï´Ù. ¿¹¸¦ µé¾î, ¹Ì±¹ ¾Ï ¿¬±¸Çùȸ´Â ÃÖ±Ù ¾Ï ¿¬±¸¸¦ °¡¼ÓÈ­ÇÏ°í ¹Ì±¹ ½Ã¹ÎÀÌ ¿¹¹æ °ËÁøÀ» ´õ ½±°í Àú·ÅÇÏ°Ô ÀÌ¿ëÇÒ ¼ö ÀÖµµ·Ï Çϱâ À§ÇØ Beau Biden Cancer MoonshotÀ» ½ÃÀÛÇß½À´Ï´Ù.

ÀÌ ½ÃÀåÀÇ ÁÖ¿ä ±â¾÷À¸·Î´Â Illumina, InVivoScribe, Ipsogen(Qiagen), Asuragen(Bio-Techne), Danaher Corporation, Abbott, SkylineDx, Adaptive Technologies, Bio-Rad Laboratories µîÀÌ ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ¾÷üµéÀº ¼¼°èÀÇ °í°´À» ´ë»óÀ¸·Î Á¦Ç° Ãâ½Ã ¹× ½ÂÀΰú °°Àº ´Ù¾çÇÑ Àü·«Àû ÀÌ´Ï¼ÅÆ¼ºê¿¡ Âü¿©Çϰí ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î, 2023³â 9¿ù, Adaptive Technologies´Â Ç÷¾×¾ÏÀÇ MRD ¸ð´ÏÅ͸µÀ» À§ÇÑ ºÐÀÚ Áø´Ü °Ë»çÀÎ clonoSEQ¸¦ À§ÇÑ ¿¡ÇÈ ÅëÇÕÀ» Ãâ½ÃÇß½À´Ï´Ù. ÀÌ ÅëÇÕÀ» ÅëÇØ ÀÇ·á ¼­ºñ½º Á¦°øÀÚ´Â ¿¡ÇÈÀÇ EHR ½Ã½ºÅÛ ³»¿¡¼­ Á÷Á¢ clonoSEQ °Ë»ç °á°ú¸¦ ÁÖ¹®ÇÏ°í °ËÅäÇÒ ¼ö ÀÖ¾î ÀÓ»ó ÀÇ»ç °áÁ¤À» °£¼ÒÈ­Çϰí ȯÀÚ Ä¡·á¸¦ °³¼±ÇÒ ¼ö ÀÖ½À´Ï´Ù.

Ç÷¾×¾Ï Áø´Ü ½ÃÀå º¸°í¼­ ÇÏÀ̶óÀÌÆ®

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý°ú ¹üÀ§

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå Ç÷¾×¾Ï Áø´Ü ½ÃÀåÀÇ º¯¼ö, µ¿Çâ, ¹üÀ§

Á¦4Àå Ç÷¾×¾Ï Áø´Ü ½ÃÀå : Á¦Ç°º°, ÃßÁ¤ ¹× µ¿Ç⠺м®

Á¦5Àå Ç÷¾×¾Ï Áø´Ü ½ÃÀå : °Ë»çº°, ÃßÁ¤ ¹× µ¿Ç⠺м®

Á¦6Àå Ç÷¾×¾Ï Áø´Ü ½ÃÀå : ÃÖÁ¾ ¿ëµµº°, ÃßÁ¤ ¹× µ¿Ç⠺м®

Á¦7Àå Ç÷¾×¾Ï Áø´Ü ½ÃÀå : Áö¿ªº°, ÃßÁ¤ ¹× µ¿Ç⠺м®

Á¦8Àå °æÀï ±¸µµ

HBR
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Blood Cancer Diagnostics Market Growth & Trends:

The global blood cancer diagnostics market size is expected to reach USD 16.04 billion by 2030, registering a CAGR of 6.87% from 2025 to 2030, according to a new report by Grand View Research, Inc. The market is driven by the increasing incidence of blood malignancies, such as leukemia, lymphoma, and myeloma. The market is further expected to grow significantly due to the increasing elderly population, which is more susceptible to chronic diseases, including blood cancer. In addition, technological advancements, including NGS and other molecular diagnostic techniques, are improving the accuracy & efficiency of diagnosis, which is likely to drive the market over the forecast period.

Over the past decade, significant advancements have been made in approaches to blood cancer diagnostics, all aimed at reducing the growing incidence of diseases and their mortality. While these advancements have been well-documented to increase early cancer detection, there have been considerable advancements. For instance, NGS has enabled the analysis of the entire genome of cancer cells, providing insights into genetic mutations that guide precise diagnosis and tailored treatments. In October 2022, OGT, a Sysmex group, introduced a range of new offerings to augment its expanding NGS product suite. Notably, the SureSeq Myeloid Plus panel was designed to identify genetic mutations associated with various Myeloid disorders, enhancing the company's capabilities in this critical area of research.

Molecular imaging techniques, such as SPECT/CT, PET, and flow cytometry, utilize molecular imaging agents to detect indicative molecular markers at different disease stages, aiding detection & monitoring. Such advancements in imaging technologies offer improved accuracy and early detection capabilities, driving the market. The global players are introducing automatic imaging tests and systems to boost their market share. For instance, in May 2023, Sysmex Corporation announced the launch of the Clinical Flow Cytometry System in Japan. The system includes Flow Cytometer XF-1600, Sample Preparation System PS-10, antibody reagents, and other related products. This system enables laboratories to automate the entire process of flow cytometry testing, from sample preparation to the reporting of measurement results, contributing to higher efficiency & testing standardization.

Governments across the world have recognized the immense healthcare burden posed by rising incidences, including hematological malignancies such as leukemia & lymphoma. In response, many countries have launched comprehensive national cancer control programs that prioritize early detection and screening efforts. For instance, the American Association of Cancer Research recently launched the Beau Biden Cancer Moonshot initiative to accelerate cancer research and make preventive screening more accessible & affordable for U.S. citizens.

Some of the key players in the market are Illumina, InVivoScribe, Ipsogen (Qiagen), Asuragen(Bio-Techne), Danaher Corporation, Abbott, SkylineDx, Adaptive Technologies, Bio-Rad Laboratories and others. These players are involved in various strategic initiatives such as product launch and approval in order to cater to a global clientele. For instance, in September 2023, Adaptive Technologies launched Epic integration for clonoSEQ, a molecular diagnostic test for MRD monitoring in blood cancers. This integration allows healthcare providers to order and review clonoSEQ test results directly within Epic's EHR system, streamlining clinical decision-making and improving patient care.

Blood Cancer Diagnostics Market Report Highlights:

Table of Contents

Chapter 1. Methodology and Scope

Chapter 2. Executive Summary

Chapter 3. Blood Cancer Diagnostics Market Variables, Trends & Scope

Chapter 4. Blood Cancer Diagnostics Market: Product Estimates & Trend Analysis

Chapter 5. Blood Cancer Diagnostics Market: Test Estimates & Trend Analysis

Chapter 6. Blood Cancer Diagnostics Market: End-use Estimates & Trend Analysis

Chapter 7. Blood Cancer Diagnostics Market: Regional Estimates & Trend Analysis

Chapter 8. Competitive Landscape

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â